2-CdA

DRUG3 trials

Sponsors

University Hospital Muenster, M.D. Anderson Cancer Center, Arbeitsgemeinschaft medikamentoese Tumortherapie

Conditions

LeukemiaLymphoma of Mucosa-Associated Lymphoid TissueMyeloid Leukemia

Phase 2

Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents

University Hospital MuensterMyeloid Leukemia

Start: 2004-03-31End: 2017-03-31Updated: 2012-05-23

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

CompletedNCT00483067

M.D. Anderson Cancer CenterLeukemia

Start: 1998-03-31End: 2008-07-31Updated: 2012-08-02

Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

CompletedNCT00656812

Arbeitsgemeinschaft medikamentoese TumortherapieLymphoma of Mucosa-Associated Lymphoid Tissue

Start: 2008-05-31End: 2011-09-30Target: 40Updated: 2013-12-24

Related Papers

Prognostic Value of Molecular Genetic Measurable Residual Disease ( <scp>MRD</scp> ) Monitoring in Pediatric Acute Myeloid Leukemia Expressing <i>KMT2A::MLLT10</i>

European Journal Of Haematology2025-08-131 citations

Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.

2016-01-2718 citations

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

2013-05-23132 citations

Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML.

2007-12-148 citations